1[1]Ruffolo RR Jr,Feuerstein GZ.The pharmacology of carvedilol:rationale for use in hypertension,coronary artery disease and congestive heart failure.Cardiovasc Drugs Ther,1997,11[Suppl 1]:247-256
2[2]Feuerstein GZ,Bril A,Ruffolo RR,et al.Protective effects of carvedilol in the myocardium.Am J Cardiol,1997,80(11A):40L-45L
3[3]Brunvand H,Kvitting PM,Rynning SE,et al.Carvedilol protects against lethel reperfusion injury through antiadrenergic machanisms.J Cardiovasc Pharmacol,1996,28 (2):409-417
4[4]Lahiri A.Neurohumoral mechanisms in congestive heart failure and the role off drugs with multiple actions:a review of carvedilol.Am J Ther,1996,3:237-247
5[5]Ma XL,Yue TL,Lopez BL,et al.Carvedilol,a new β-adrenoreceptor ischemia reperfusion injury in hypercholestrolemic rabbits.J Pharmacol Exp Ther,1995,273 (1):64-71
6[6]Yue TL,Wang X,Gu JL,et al.Carvedilol,a novel vasodilating beta adrenoceptor antagonist,prevents low-density lipoprtotein (LDL)-enhanced leukocyte adhesion to endothelial cells by inhibition of LDL oxidation.J Eur J Pharmacol,1995,294(2-3):584-589
7[7]Feuerstein GZ,Bril A,Ruffolo RR,et al.Protective effects of carvedilol in the myocardium.Am J Cardiol,1997,80 (11A):41 L-45 L
8[8]Cheng HY,Randall CS,Holl WW,et al.Carvedilol-liposome interaction:evidence for strong association with the hydrophobic region of lipid bilayers.Biochem Biolphys Acta,1996,128 (1):20-28
9[9]Khandoudi N,Albadine JP,Bril A.Comparative effects of carvedilol and metoprolol on cardiac ischemic-referfusion injury.J Cardiovasc Pharmacol,1998,32(3):443-451
10[10]Feuerstein GZ,Yue TL,Cheng HY,et al.Myocardiol protection by the novel vasidilating beta-bloker,Carvedilol:potential relevance of antioxidant activity.J Hypertens,1993,11[Suppl 4]:S41-S48
